Table 2. Second line phase III trial results with chemotherapy +/− Antiangiogenic agents in mCRC.
| Chemotherapy/Antiangiogenic Agent | TRIAL | No patients | PFS (months) | HR (P) | OS (months) | HR (P) |
|---|---|---|---|---|---|---|
| FOLFOX4/Bevacizumab [3] | E3200 | 829 | 7.3 vs. 4.7 | 0.61 (< 0.0001) | 12.9 vs. 10.8 | 0.75 (0.0011) |
| Chemotherapy switch/Bevacizumab [22] | ML18147 | 820 | 5.7 vs. 4.1 | 0.68 (< 0.0001) | 11.2 vs. 9.8 | 0.81 (0.0062) |
| Chemotherapy switch/Bevacizumab [23] | BEBYP | 185 | 6.8 vs. 5.0 | 0.70 (0.010) | 14.1 vs. 15.5 | 0.77 (0.043) |
| FOLFIRI/Aflibercept [4] | VELOUR | 1226 | 6.9 vs. 4.67 | 0.758 (< 0.0001) | 13.5 vs. 12.1 | 0.817 (0.0032) |